The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Erythropoietin Biology in Cancer
Open accessAbstract
Erythropoietin (Epo) has long been known to be the principal hematopoietic growth factor that regulates cellular proliferation and differentiation along the erythroid lineage. Recent studies have shown that Epo is a pleiotropic cytokine that is proangiogenic and exerts broad tissue-protective effects in diverse nonhematopoietic organs. Recombinant Epo (rEpo) has been widely used in the clinic to prevent or treat malignancy-associated anemia. A series of clinical trials have documented the efficacy of rEpo in reducing RBC transfusion requirements and improving quality of life in cancer patients, and a recent meta-analysis suggested a positive effect on survival. However, two randomized trials reported negative outcomes with rEpo, as patients in the rEpo arm fared worse than their placebo-treated counterparts with respect to progression-free survival. The expression of Epo receptor (EpoR) in cancer cells has raised the possibility that exogenous rEpo may exert direct effects on tumor cells associated with the potential for stimulation of proliferation, inhibition of apoptosis, or modulation of sensitivity to chemoradiation therapy. The presence of an autocrine-paracrine Epo-EpoR system in tumors and potential effects of Epo on tumor microenvironment and angiogenesis are consistent with a complex biology for Epo-EpoR signaling in cancer that requires further research. This review describes Epo and EpoR biology, focusing on the pleiotropic effects of Epo on nonhematopoietic tissues as well as the expression and function of EpoR in cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Erythropoietin regulates tumour growth of human malignancies
Yasuda, Y. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg060 · Cited by 257
Expression of erythropoietin by the human placenta
Conrad, K. P., Benyo, D. F., Westerhausen‐Larsen, A., & Miles, T. M. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.7.8635693 · Cited by 138
Cited by
Bennett, C. L. (2008) · JAMA · doi:10.1001/jama.299.8.914 · Cited by 731
Erythropoietin after a century of research: younger than ever
Jelkmann, W. (2007) · European Journal of Haematology · doi:10.1111/j.1600-0609.2007.00818.x · Cited by 367
Alternative Vascularization Mechanisms in Cancer
Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359
Liang, K., Esteva, F. J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.-Y., Li, Y., Li, X., Chen, C.-T., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.025 · Cited by 139
Predictive mathematical models of cancer signalling pathways
Bachmann, J., Raue, A., Schilling, M., Becker, V., Timmer, J., & Klingmüller, U. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02492.x · Cited by 63
Metadata
- Authors
- Hardee, M. E., Arcasoy, M. O., Blackwell, K. L., Kirkpatrick, J. P., & Dewhirst, M. W.
- Venue
- Clinical Cancer Research
- Published
- 2006-01-15
- Volume
- 12
- Issue
- 2
- Pages
- 332-339
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2162885883
- Cited by
- 223
- References
- 3
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Erythropoietin Biology in Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-1771
- The paper
- Hardee, M. E., Arcasoy, M. O., Blackwell, K. L., Kirkpatrick, J. P., & Dewhirst, M. W. (2006). Erythropoietin Biology in Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-1771
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.